ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

9527	Companies
187412	Keywords
119446	Articles
100176	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 12/09/2025 at 07:35, 6 days 8 hours ago

OSE Immunotherapeutics' new strategic plan for 2026-2028

Strategic Plan Funding OSE Immunotherapeutics Lusvertikimab Tedopi® Phase 3
BRIEF

published on 12/09/2025 at 07:35, 6 days 8 hours ago

OSE Immunotherapeutics Announces Strategic Plan for 2026–2028

Strategic Plan Financial Strategy Scientific Leadership Tedopi Trial Lusvertikimab Development
PRESS RELEASE

published on 12/09/2025 at 07:30, 6 days 8 hours ago

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership

Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
BRIEF

published on 10/15/2025 at 19:05, 1 month 30 days ago

OSE Immunotherapeutics Reports 2025 First Half Financial Results

Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
PRESS RELEASE

published on 10/15/2025 at 19:00, 1 month 30 days ago

OSE Immunotherapeutics Reports First Half 2025 Financial Results
OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7%

Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
BRIEF

published on 10/09/2025 at 16:02, 2 months 6 days ago

OSE Immunotherapeutics: End of a concerted action between shareholders

Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
BRIEF

published on 09/30/2025 at 19:35, 2 months 14 days ago

OSE Immunotherapeutics: Reorganization of the Board of Directors

Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
PRESS RELEASE

published on 09/30/2025 at 19:30, 2 months 14 days ago

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
OSE Immunotherapeutics renews Board of Directors and elects Dr. Markus Cappel as Chairman. Shareholders vote on key appointments

Board Of Directors Shareholders General Meeting OSE Immunotherapeutics Dr. Markus Cappel
BRIEF

published on 09/26/2025 at 07:05, 2 months 19 days ago

Strategic Partnership for Innovation in Immunotherapy

Strategic Partnership Oncology Industrial Support Immunotherapy Innovation Collaborative Research
PRESS RELEASE

published on 09/26/2025 at 07:00, 2 months 19 days ago

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
OSE Immunotherapeutics, Inserm Transfert, and Nantes University form a strategic partnership to advance immunotherapy for oncology, inflammation, and autoimmunity. The collaboration combines academic research and industrial expertise

Innovation Partnership Oncology Collaboration Immunotherapy

1 2 ... 5

Accesswire

Published on 12/15/2025 at 15:00, 1 hour 7 minutes ago

Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 1 hour 7 minutes ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 1 hour 37 minutes ago

Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 2 hours 7 minutes ago

Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum
Published on 12/15/2025 at 13:30, 2 hours 37 minutes ago

Greenlane Announces Results of Annual Meeting of Stockholders, Canopy Growth Co Founder Bruce Linton Joins Greenlane's Board of Directors

View all ACCESSWIRE

EQS Group

Published on 12/15/2025 at 15:50, 17 minutes ago

Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen
Published on 12/15/2025 at 15:49, 18 minutes ago

Mutares submits an irrevocable offer to acquire Venator Ultramarine Blue Pigments business from Venator France SAS
Published on 12/15/2025 at 15:45, 22 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/15/2025 at 15:44, 23 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/15/2025 at 15:43, 24 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc

Les Echos

Published on 12/15/2025 at 11:50, 4 hours 17 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 22 hours ago

Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/12/2025 at 09:15, 3 days 6 hours ago

CHANGE IN THE SHARE CAPITAL
Published on 12/11/2025 at 19:23, 3 days 20 hours ago

Eiffage is joining the CAC 40 index
Published on 12/11/2025 at 08:30, 4 days 7 hours ago

Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe

View all LES ECHOS COMFI WIRE